Next Article in Journal
Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
Previous Article in Journal
Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 28
Issue 6
10.3390/curroncol28060425
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective

by
Flavia Bociort
1,†,
Ioana Gabriela Macasoi
2,3,†,
Iasmina Marcovici
2,3,*,
Andrei Motoc
1,
Cristina Grosu
2,
Iulia Pinzaru
2,3,
Crina Petean
2,
Stefana Avram
2,3 and
Cristina Adriana Dehelean
2,3
1
Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
2
Faculty of Pharmacy, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
3
Research Center for Pharmaco-Toxicological Evaluations, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Curr. Oncol. 2021, 28(6), 5054-5066; https://doi.org/10.3390/curroncol28060425
Submission received: 11 October 2021 / Revised: 14 November 2021 / Accepted: 1 December 2021 / Published: 2 December 2021
Browse Figures
Versions Notes

Abstract

Malignant melanoma (MM) represents the most life-threatening skin cancer worldwide, with a narrow and inefficient chemotherapeutic arsenal available in advanced disease stages. Lupeol (LUP) is a triterpenoid-type phytochemical possessing a broad spectrum of pharmacological properties, including a potent anticancer effect against several neoplasms (e.g., colorectal, lung, and liver). However, its potential as an anti-melanoma agent has been investigated to a lesser extent. The current study focused on exploring the impact of LUP against two human MM cell lines (A375 and RPMI-7951) in terms of cell viability, confluence, morphology, cytoskeletal distribution, nuclear aspect, and migration. Additionally, the in ovo antiangiogenic effect has been also examined. The in vitro results indicated concentration-dependent and selective cytotoxicity against both MM cell lines, with estimated IC50 values of 66.59 ± 2.20 for A375, and 45.54 ± 1.48 for RPMI-7951, respectively, accompanied by a reduced cell confluence, apoptosis-specific nuclear features, reorganization of cytoskeletal components, and inhibited cell migration. In ovo, LUP interfered with the process of angiogenesis by reducing the formation of neovascularization. Despite the potential anti-melanoma effect illustrated in our in vitro-in ovo study, further investigations are required to elucidate the underlying LUP-induced effects in A375 and RPMI-7951 MM cells.
Keywords: lupeol; skin cancer; malignant melanoma cells; angiogenesis lupeol; skin cancer; malignant melanoma cells; angiogenesis

Share and Cite

MDPI and ACS Style

Bociort, F.; Macasoi, I.G.; Marcovici, I.; Motoc, A.; Grosu, C.; Pinzaru, I.; Petean, C.; Avram, S.; Dehelean, C.A. Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective. Curr. Oncol. 2021, 28, 5054-5066. https://doi.org/10.3390/curroncol28060425

AMA Style

Bociort F, Macasoi IG, Marcovici I, Motoc A, Grosu C, Pinzaru I, Petean C, Avram S, Dehelean CA. Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective. Current Oncology. 2021; 28(6):5054-5066. https://doi.org/10.3390/curroncol28060425

Chicago/Turabian Style

Bociort, Flavia, Ioana Gabriela Macasoi, Iasmina Marcovici, Andrei Motoc, Cristina Grosu, Iulia Pinzaru, Crina Petean, Stefana Avram, and Cristina Adriana Dehelean. 2021. "Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective" Current Oncology 28, no. 6: 5054-5066. https://doi.org/10.3390/curroncol28060425

APA Style

Bociort, F., Macasoi, I. G., Marcovici, I., Motoc, A., Grosu, C., Pinzaru, I., Petean, C., Avram, S., & Dehelean, C. A. (2021). Investigation of Lupeol as Anti-Melanoma Agent: An In Vitro-In Ovo Perspective. Current Oncology, 28(6), 5054-5066. https://doi.org/10.3390/curroncol28060425

Article Metrics

Back to TopTop